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ABSTRACT
Dilated cardiomyopathy is a prevalent and often fatal disease in humans and dogs.
Indeed dilated cardiomyopathy is the third most common form of cardiac disease in
humans, reported to affect approximately 36 individuals per 100,000 individuals. In
dogs, dilated cardiomyopathy is the secondmost common cardiac disease and is most
prevalent in the Irish Wolfhound, Doberman Pinscher and Newfoundland breeds.
Dilated cardiomyopathy is characterised by ventricular chamber enlargement and
systolic dysfunction which often leads to congestive heart failure. Although multiple
human loci have been implicated in the pathogenesis of dilated cardiomyopathy,
the identified variants are typically associated with rare monogenic forms of dilated
cardiomyopathy. The potential for multigenic interactions contributing to human
dilated cardiomyopathy remains poorly understood. Consistent with this, several
known human dilated cardiomyopathy loci have been excluded as common causes of
canine dilated cardiomyopathy, although canine dilated cardiomyopathy resembles
the human disease functionally. This suggests additional genetic factors contribute
to the dilated cardiomyopathy phenotype.This study represents a meta-analysis of
available canine dilated cardiomyopathy genetic datasets with the goal of determining
potential multigenic interactions relating the sex chromosome genotype (XX vs. XY)
with known dilated cardiomyopathy associated loci on chromosome 5 and the PDK4
gene in the incidence and progression of dilated cardiomyopathy. The results show
an interaction between known canine dilated cardiomyopathy loci and an unknown
X-linked locus. Our study is the first to test a multigenic contribution to dilated
cardiomyopathy and suggest a genetic basis for the known sex-disparity in dilated
cardiomyopathy outcomes.
Subjects Bioinformatics, Genetics, Veterinary Medicine, Cardiology, Medical Genetics
Keywords Dilated cardiomyopathy, PDK4, Canine, Multigenic, Human
INTRODUCTION
Dilated cardiomyopathy (DCM) is a prevalent and often fatal disease requiring clinical
management in humans and dogs (Egenvall, Bonnett & Ha¨ggstro¨m, 2006; Hershberger,
Morales & Siegfried, 2010). DCM is the second most common cardiac disease in dogs and
is characterised by ventricular chamber enlargement and systolic dysfunction which often
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leads to congestive heart failure (Egenvall, Bonnett & Ha¨ggstro¨m, 2006). The aetiology of
DCM is complex. Genetic factors, myocardial ischemia, hypertension, toxins, infections
and metabolic defects have been implicated (McNally, Golbus & Puckelwartz, 2013). To
date, mutations in over 50 genes have been associated with DCM in humans; however,
mutations in the most prevalent DCM related genes only account for approximately 50%
of patients with DCM (Posafalvi et al., 2013). In human DCM genetic testing where a
panel of approximately 50 loci are tested concurrently, often more than one locus can
be implicated in the disease (McNally, Golbus & Puckelwartz, 2013), suggesting multiple
genetic factors cooperate in DCM aetiology.
Canine DCM is phenotypically similar to human DCM (Shinbane et al., 1997). As
outlined below, to date mutations in only two genes (PDK4 and STRN) and a single
nucleotide polymorphism (SNP) on chromosome 5 have been associated with canine
DCM (Mausberg et al., 2011;Meurs et al., 2012;Meurs et al., 2013), suggesting additional
genetic causes remain unknown. While canine studies have sometimes been limited by
small sample size (typically less than 10 individuals), those studies with larger sample
numbers (greater than 50 individuals) have also frequently failed to find significant
associations with DCM (e.g., Philipp et al., 2007; Philipp, Vollmar & Distl, 2008;Wiersma
et al., 2008). One possible explanation for the challenges in identifying DCM associated
loci in humans and dogs is that even within an extended family or breed, genetic variation
at a single locus cannot explain the development of DCM. Indeed dog breeds can be
considered as large families, with dogs within a breed more related to each other than
dogs of other breeds (Parker et al., 2004). In the same way that some human families are
affected by DCM, a subset of dog breeds are affected by DCMmore frequently than others
(Egenvall, Bonnett & Ha¨ggstro¨m, 2006). Dobermans Pinschers (hereafter Dobermans)
are particularly affected by DCM, with both a high prevalence (58.2% in European
Dobermans) and severity with DCM associated death often occurring within 8 weeks
of diagnosis (Calvert et al., 1997;Wess et al., 2010). In dogs, diagnosis is usually at the onset
of clinical symptoms of heart failure. But there is an extended pre-clinical phase, during
which if treatment can be effective by prolonging the onset of heart failure (Summerfield
et al., 2012). In this phase left ventricular dilation and dysfunction begins, and can be
accompanied by ventricular premature complexes (Singletary et al., 2012), Median life
expectancy of DCM affected European Dobermans is 7.8 years, compared with 11 years for
unaffected European Dobermans (Proschowsky, Rugbjerg & Ersbøll, 2003; Egenvall, Bonnett
& Ha¨ggstro¨m, 2006). A deletion in a splice site of the PDK4 gene (Meurs et al., 2012) and a
SNP on chromosome 5 (Mausberg et al., 2011) in Dobermans are two of only three canine
DCM mutations identified to date. While these two loci are associated with Doberman
DCM, individually neither locus explains all cases of Doberman DCM (Mausberg et al.,
2011; Meurs et al., 2012). Individuals heterozygous at the Chr5 SNP are more likely to
develop DCM, but there aremanyDCM cases homozygous for the healthy allele (Mausberg
et al., 2011). While PDK4 genotypes are less definite predictors of DCM, with both affected
and unaffected individuals possessing the three possible genotypes, the 16bp PDK4 splice
site deletion is found more frequently in North American Dobermans with DCM than
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those without DCM (Meurs et al., 2012). However an analysis of European Dobermans
failed to identify an association between PDK4 and DCM (Owczarek-Lipska et al., 2013),
suggesting additional unknown factors influence the effect of PDK4 in predisposing
individuals to DCM. Thus novel genetic causes of canine DCM remain to be identified
(Mausberg et al., 2011; Philipp et al., 2012).
In this study we developed genetic models to test the influence of unknown genetic
factors to predict which DCM-associated genotype combinations are likely to develop
DCM. Using this method, we provide evidence for a sex-linked genetic influence on
known DCM loci in the pathogenesis of canine DCM. Our study is the first to propose
amultigenic contribution to canine DCM.
MATERIALS AND METHODS
Model development
A literature search of the Pubmed andWeb of Science database using the following search
terms: “Doberman DCM loci,” “Doberman Dilated Cardiomyopathy loci,” “Doberman
DCM gene,” “Doberman Dilated Cardiomyopathy gene,” “Doberman DCM locus” and
“Doberman Dilated Cardiomyopathy locus” (Fig. 1) identified thirty unique records. This
search identified two loci associated with DCM in North American Dobermans (Meurs et
al., 2012;Mausberg et al., 2011). By combining the genotypes from the identified Dober-
man DCM associated loci, and additional putative loci, predictive models were developed
and tested against observed DCM incidence data. All genotype combinations for the DCM
associated SNP identified on chromosome 5 (TIGRP2P73097:CFA5:g.53,941,386T>C,
CanFam2.1) (Mausberg et al., 2011) and the PDK4 (GeneID:482310) splice site deletion
(CFA14:g.20,829,667 20,829,682del, CanFam3.1) (Meurs et al., 2012) were determined.
Further analysis determined which genotype combinations were likely to lead to DCM.
Some genotypes are definitive; all individuals homozygous for the susceptibility allele at
CFA5:g.53,941,386T>C develop DCM (Mausberg et al., 2011).
Determining which genotypes develop DCM
Five genetic models incorporating genotypes at multiple observed and hypothetical loci
were developed including: 1. two known DCM loci; 2. two known loci + 50% of the
population more susceptible to developing DCM; 3. two known loci+ a novel autosomal
dominant DCM locus; 4. two known loci+ a novel autosomal recessive DCM locus; 5. two
known loci+ a novel additive DCM locus and 6. two known loci+ a novel X-linked DCM
locus. For each model, different biologically feasible phenotype outcomes were tested for
each genotype combination to establish the best fit of the model to the observed DCM
incidence data. Each model was subject to the following constraints: individuals that are
homozygous CC at the Chr5 SNP develop DCM, and individuals with no susceptibility
alleles are healthy.
Model testing
For each model, the frequency of each genotype combination was calculated by multi-
plying the genotype frequencies using PDK4 and Chr5 frequencies (Table 1) obtained
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Figure 1 Prisma flow diagram.
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Table 1 Genotype frequencies assuming Hardy Weinberg equilibrium. Allele frequencies taken from
Mausberg et al. (2011) and Owczarek-Lipska et al. (2013).
PDK4 Chr5 SNP
Genotype Freq Genotype Freq
WtWt 0.72 TT 0.74
Wt del 0.26 TC 0.24
Del del 0.02 CC 0.02
from Owczarek-Lipska et al. (2013) and Mausberg et al. (2011). A range of frequencies
were tested for each hypothetical loci. For example, for the model incorporating only
PDK4 and Chr5 variants, one genotype combination is WtWt-TT. The frequency of this
genotype combination is the product of the frequency of WtWt and the frequency of TT
in the population. From the combined genotype frequencies, the expected numbers of
individuals with each genotype combination were calculated by multiplying the frequency
by the number of individuals in the study to be compared with (182 when compared
with Mausberg et al. (2011) and Owczarek-Lipska et al. (2013)). Thus, the numbers of
individuals in the model that were, for example, WtWt healthy and WtWt DCM were
obtained by summing the numbers in each category. Having obtained the numbers of
affected and unaffected individuals that the model predicts for each genotype, these were
tested against the observed data using a χ2 test. Where additional putative DCM loci were
included in the model, several allele frequencies were tested. However, as GWAS studies
have previously been carried out (Mausberg et al., 2011;Meurs et al., 2012), it is unlikely
that additional DCM alleles are at higher frequencies than those already identified. For this
reason, DCM allele frequencies over 0.5 were not tested. If the model is a good fit of the
observed data, the χ2 test statistic will be non-significant.
The proportion of the population that the model predicts to have DCMwas determined
by taking the sum of all the genotype combined frequencies that lead to DCM in
the model. For example, for the model incorporating just the two known loci this is
0.0144+ 0.0624+ 0.0052+ 0.0048+ 0.0004 = 0.0872—(Table S1). This proportion
was then compared to the observed DCM frequency of 0.582 (Wess et al., 2010).
For most models, it must be assumed that there is no difference in DCM incidence
between the sexes, as an effect of sex has not been included. For the DCMmodel testing
a 50% increased susceptibility, where it is biologically feasible that males are more
susceptible and the models incorporate an additional X-linked locus, it is possible to
calculate the proportion males and females that develop DCM. While males develop
clinical symptoms earlier and appear to be more severely affected, there are indications
that the sex of those affected by DCM is close to 50%male, 50% female (Wess et al., 2010),
so we would expect ourmodel to reflect this.
Odds ratios of each genotype and allele developing DCM for each model were obtained
by testing each genotype against the other two combined and each allele against the other.
Odds ratios are the odds/probability of an individual with a particular genotype or allele
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Table 2 Genotype odds ratios from the original studies reporting an association. Ratios from the
PDK4 locus (Meurs et al., 2012) and Chromosome 5 SNP (Mausberg et al., 2011). The PDK4 χ2 test
results indicate that the WtWt genotype significantly associated with non-DCM and the WtDel genotype
significantly associated with DCM at the 0.01 significance level, the DelDel genotype odds ratio whilst
different from the null result of 1, is not significantly so. For the chromosome 5 SNP all individuals that
are CC in the original study developed DCM, thus and odds ratio and confidence interval cannot be
calculated, but χ2 tests can be performed on the data. TT is significantly associated with non-DCM and
the TC and CC genotypes are significantly associated with DCM at the 0.01 significance level.
Genotype Odds ratio 95% CI
PDK4 WtWt 0.14 0.07, 0.32
PDK4 WtDel 5.21 2.70, 12.09
PDK4 DelDel 1.14 0.41, 3.18
Chr5 TT 0.11 0.05, 0.24
Chr5 TC 6.23 2.78, 14.00
Chr5 CC NA NA
Table 3 Allele odds ratios from the original studies reportingDCMassociations. Allele odds rations at
the PDK4 locus (Meurs et al., 2012) and Chromosome 5 SNP (Mausberg et al., 2011). The χ2 test results
indicate that each susceptibility (Del and C respectively) allele is significantly associated with DCM and
the alternate allele significantly associated with non-DCM at the 0.01 significance level.
Allele Odds ratio 95% CI
PDK4 Wt 0.38 0.23, 0.64
PDK4 Del 2.63 1.57, 4.42
Chr5 T 0.12 0.06, 0.26
Chr5 C 8.11 3.85, 17.09
developing DCM compared, by dividing one by the other, to the odds of an individual
with all other genotypes or alleles developing DCM, with and odds ratio greater than one
associated with the trait of interest and an odds ratio of less than one not associated (Bland
& Altman, 2000). For example the odds ratio for TT in the published data fromMausberg
et al. (2011) is calculated in the following way. There are 45 individuals that are TT DCM
and 85 TT healthy the odds of a TT individual developing DCM are 45/85 (0.53), there are
43 individuals which are TC or CC with DCM and 9 individuals that are TC or CC healthy
so the odds of these individuals developing DCM are 43/9 (4.78) the odds ratio divides
the genotype of interest odds by the ‘others’ odds to give the odds ratio or 0.11. To assess
the significance of these ratios χ2 tests were performed on the 2× 2 tables—in the above
example the four groups are TT-DCM, TT-healthy, TC or CC-DCM, TC or CC-healthy.
If the model is a good fit to the observed data it is expected that the odds ratios are of a
similar pattern and significance, e.g., TT, small—significantly not associated with DCM;
TC, large—significantly associated with DCM; CC, not possible to test—not testable, as for
the Chr5 SNP in Table 2. Odds ratios of both genotypes and alleles were obtained from the
original studies (Tables 2 and 3).
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Table 4 Genotype-phenotype decision descriptions for each model. Models represent: 1. the two
known DCM loci; 2. two known loci + 50% of the population is more susceptible to developing DCM;
3. two known DCM loci combined with a novel autosomal dominant DCM locus; 4. two known DCM
loci combined with an autosomal recessive locus; 5. two known DCM loci combined with a an additional
DCM locus that is additive and 6. two known DCM loci combined with an X-linked DCM locus.
Model Genotype—phenotype decision description, in addition to the rules:
1. DCM develops when both the PDK4 locus and Chr5 SNP have at least one DCM susceptibility
allele.
2. 50% more susceptible only need to have a single DCM susceptibility allele at either locus to
develop DCM while the 50% less susceptible to DCM require at least one DCM susceptibility
allele at both loci to develop DCM.
3. All individuals that have a susceptibility allele at the additional locus develop DCM. Those indi-
viduals with no susceptibility alleles at the additional locus need at least one DCM susceptibility
allele at both of the other loci to develop DCM.
4. All homozygous susceptible individuals at the additional locus develop DCM. For individuals
that are heterozygous at the additional locus, DCM occurs when combined with another
DCM susceptibility allele, while homozygous unsusceptible individuals need at least one DCM
susceptibility allele at both of the other loci to develop DCM.
5. All homozygous susceptible individuals at the additional locus develop DCM. Heterozygotes and
homozygous unsusceptible individuals need at least one DCM susceptibility allele at both of the
other loci to develop DCM.
6. X linked susceptible DCM locus males can either possess a single unsusceptible X (XY) or a single
susceptible x (xY), while females can be unsusceptible X homozygotes (XX), heterozygotes (Xx)
or susceptible x homozygotes (xx). Unsusceptible X males (XY) are phenotypically identical to
unsusceptible X homozygotes (XX) with these individuals requiring at least one DCM suscep-
tibility allele at both of the other loci to develop DCM. All individuals that possess a susceptible
X (xY and xx individuals) develop DCM in this model while heterozygotes (Xx) only require a
single DCM susceptibility allele at one of the other loci to develop DCM.
RESULTS
Following the constraints stated in the methods and using biologically feasible reasoning
each model was optimised to best fit the observed data. For each model the genotype-
phenotype decision descriptions are shown in Table 4. Tables of each model are in
Supplemental Information.
Comparing model predictions with observed data
The χ2 test values comparing predicted numbers with observed numbers of DCM and
healthy individuals at each genotype ranged from 4.35 to 7766.06. A χ2 value of less
than 11.07 indicates there is no significant difference between predicted and observed
genotype-phenotype data, (5% significance level, with 5 degrees of freedom). Values less
than 15.09 represent predictions not significantly different to observed values at the 1%
significance level. χ2 values less than these critical values are indicated in Table 5.
Model predicted DCM population frequency and sex incidence
For each model, the predicted DCM frequency was calculated to provide an additional
method to test the accuracy of the model. The DCM frequency in the European Doberman
population is estimated to be 58.2% (Wess et al., 2010), therefore accurate models should
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Table 5 χ2 test statistic results comparing predicted ofDCMandhealthy individuals at each genotype
from each model with observed numbers of DCM and healthy individuals at each genotype. Model
data based on data fromMausberg et al. (2011)–Chr5 SNP and Owczarek-Lipska et al. (2013)–PDK4.
χ
2 test statistic for each model
Model PDK4 Chr5
1. 1269.23 7766.06
2. 110.45 596.68
DCM allele freq 0.5 0.4 0.3 0.2 0.5 0.4 0.3 0.2
3. 32.47 29.25 51.42 113.35 6.58** 7.69** 24.30 69.27
4. 26.24 74.61 171.69 379.06 31.65 67.45 145.76 360.86
5. 88.95 31.36 4.97** 4.36** 114.72 53.10 23.13 17.21
DCMX allele (x) freq 0.5 0.4 0.3 0.2 0.5 0.4 0.3 0.2
6. 10.57** 10.06** 25.38 71.30 11.32* 9.29** 19.55 52.86
Notes.
* not significant at 1% significance level.
** not significant at 5% significance level.
Table 6 DCM frequency predicted by eachmodel.
Model DCM freq for each model
1. 0.0872
2. 0.2772
DCM allele freq 0.5 0.4 0.3 0.2
3. 0.5054* 0.415648 0.328952 0.245321
4. 0.3154 0.233248 0.169352 0.123712
5. 0.7718 0.671392* 0.552728* 0.415808
DCMX allele (x) freq 0.5 0.4 0.3 0.2
6. 0.5245* 0.433984 0.350432 0.257536
Notes.
* indicates frequencies within 0.1 of the reported frequency (0.582 (Wess et al., 2010)) in the European Doberman pincher
population.
predict a similar frequency. The frequencies predicted by each model are displayed in
Table 6 (see also Table S2), with those within 10% of the reported frequency highlighted
as accurate models. Further to this the proportion of males and females that each model
predicts to develop DCM were calculated. Whilst most models do not account for sex
and assume equal numbers of males and females affected, two models tested either a 50%
increase in male susceptibility or an additional X-linked locus. Based on reported DCM
incidence for a model to fit the observed data it is expected that similar proportions of
males and females develop DCM. Table 7 shows that irrespective of the frequency of the
novel susceptibility allele the model incorporating a novel X linked DCM locus gives
similar proportions of affectedmales and females.
Odds ratios
For the Chr5 SNP there are no odds ratio for CC, as all individuals that are CC develop
DCM in both the original study (Mausberg et al., 2011) and models so odds ratios cannot
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Table 7 Proportion of males and females predicted to be affected by DCM bymodels 2 and 6.
Proportion DCM
Model Male Female
2. 0.4672 0.0872
6.
DCM X allele (x) freq 0.5 0.5436 0.5054
DCM X allele (x) freq 0.4 0.45232 0.415648
DCM X allele (x) freq 0.3 0.36104 0.339824
DCM X allele (x) freq 0.2 0.26976 0.245312
Table 8 Odds ratios of each PDK4 genotype with χ2 significance.
PDK4 genotype odds ratio
Model wtwt wtdel deldel wtwt wtdel deldel wtwt wtdel deldel wtwt wtdel deldel
Individual loci 0.78 1.29 1.11
1. 0.06** 12.91** 3.85
2. 0.1** 9.41** 4.6
DCM allele freq 0.5 0.4 0.3 0.2
3. 0.14** 6.70** 4.42 0.15** 6.31** 3.98 0.15** 6.21** 3.69 0.14** 6.47** 3.53
4. 0.45* 2.17* 1.76 0.35** 2.73** 2.03 0.25** 3.77** 2.43 0.15** 5.82** 2.98
5. 0.7 1.42 1.31 0.67 1.49 1.36 0.62 1.6 1.43 0.53 1.84 1.58
DCMX allele (x) freq 0.5 0.4 0.3 0.2
6. 0.31** 3.12** 2.4 0.30** 3.23** 2.41 0.28** 3.41** 2.45 0.24** 3.89** 2.59
Notes.
* significant at 5% level
** significant at 1% level
be calculated. Despite this a χ2 test can be performed on the counts of affected and
unaffected individuals observed and predicted with the genotype so the significance of
the results was obtained. For the Chr5 SNP, 12 of 18 models (Table 9), and 15 of the
allele odds ratios are consistent with the original studies (Table 11). The PDK4 deletion
association was identified in the North American Doberman population; in the European
population, the odds ratios (Tables 8 and 10) are not significantly different from the null
result of 1. Once combined with additional loci, similar significant likelihood ratios as the
North American population are obtained for 13 of 18models (Tables 8 and 10).
Selecting the most realistic model
For a model to be considered plausible, it should predict similar numbers of affected
and unaffected individuals at each genotype as observed in Mausberg et al. (2011)
and Owczarek-Lipska et al. (2013), predict similar DCM frequency as reported in the
population (Wess et al., 2010), and give odds ratios of genotypes and alleles similar to those
from the studies which report an association. To assist in determining which models meet
these requirements, Table 12 shows which conditions each model meets (Tables S3–S6).
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Table 9 Odds ratios of each Chr5 SNP genotype with χ2 significance.
Model Chr5 genotype odds ratio
TT TC CC TT TC CC TT TC CC TT TC CC
Individual loci 0.11** 6.23** –**
1. 0.02** 11.37** –**
2. 0.09** 9.23** –**
DCM allele freq 0.5 0.4 0.3 0.2
3. 0.14** 6.74** – 0.14** 6.34** –* 0.13** 6.25** –** 0.12** 6.56** –**
4. 0.35** 2.33* –** 0.25** 2.96** –** 0.16** 4.13** –** 0.08** 6.45** –**
5. 0.67 1.51 – 0.61 1.57 – 0.54 1.7 – 0.44* 1.96 –*
DCMX allele (x) freq 0.5 0.4 0.3 0.2
6. 0.29** 3.22** – 0.27** 3.34** –* 0.24** 3.55** –** 0.19** 4.08** –**
Notes.
* significant at 5% level
** significant at 1% level
Table 10 Odds ratios of each PDK4 allele with χ2 significance.
Model PDK4 allele odds ratio
Wt Del Wt Del Wt Del Wt Del
Individual loci 0.81 1.23
1. 0.17** 5.84**
2. 0.16** 6.22**
DCM allele freq 0.5 0.4 0.3 0.2
3. 0.19** 5.37** 0.2** 4.91** 0.22** 4.65** 0.22** 4.57**
4. 0.52* 1.94* 0.43** 2.32** 0.34** 2.94** 0.22** 3.91**
5. 0.74 1.36 0.71 1.36 0.66 1.51 0.59 1.69
DCMX allele (x) freq 0.5 0.4 0.3 0.2
6. 0.37** 2.71** 0.36** 2.76** 0.35** 2.94** 0.32** 3.1**
Notes.
* significant at 5% level
** significant at 1% level
From this it is possible to see that no model meets all the conditions, but two similar
models, the models incorporating the two identified loci and an additional X-linked DCM
locus with the novel DCM allele frequency at 0.4 and 0.5, meet all but one condition each.
An additional exploration of the additional X-linked DCM allele frequency indicates that
an X-linked DCM allele frequency between 0.4 and 0.5 leads to all conditions beingmet.
DISCUSSION
This study used publicly available data to test the prediction that genetic models
incorporating multiple factors can better explain and predict the incidence of canine
DCM than those utilising a single factor. Until now, the possibility that multiple genes
combine to influence DCM phenotype has been proposed, but has not yet been tested,
despite an established role for multiple loci in related diseases (Ingles et al., 2005; Xu et al.,
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Table 11 Odds ratios of each Chr5 SNP allele with χ2 significance.
Model Chr5 allele odds ratio
T C T C T C T C
Individual loci 0.15** 6.64**
1. 0.08** 12.33**
2. 0.13** 7.49**
DCM allele freq 0.5 0.4 0.3 0.2
3. 0.19** 5.34** 0.19** 5.37** 0.18** 5.55** 0.16** 6.07**
4. 0.36** 2.76** 0.28** 3.62** 0.20** 5.08** 0.16** 7.68**
5. 0.72 1.38 0.64 1.38 0.55 1.82 0.45** 2.23**
DCMX allele (x) freq 0.5 0.4 0.3 0.2
6. 0.33** 3.02** 0.3** 3.28** 0.27** 5.08** 0.23** 4.35**
Notes.
* significant at 5% level
** significant at 1% level
Table 12 Adherence to model. Table shows whether each model (with the new DCM allele frequency indicated) meets each condition, Y the
condition is met, x the condition is not met. The number of conditions not met is also indicated.
χ
2 OR genotype OR allele
Model PDK4 Chr5 SNP DCM freq PDK4 Chr5 SNP PDK4 Chr5 SNP Number of conditions
not met
Individual – – – x Y x x 3
1. x x x Y Y Y x 4
2. x x x Y Y Y x 4
3.
0.5 x x Y Y x Y Y 3
0.4 x x x Y Y Y Y 3
0.3 x x x Y Y Y Y 3
0.2 x x x Y Y Y Y 3
4.
0.5 x x x Y Y Y Y 3
0.4 x x x Y Y Y Y 3
0.3 x x x Y Y Y Y 3
0.2 x x x Y Y Y Y 3
5.
0.5 x x x x x x x 7
0.4 x x Y x x x x 6
0.3 Y x Y x x x x 5
0.2 Y x x x x x Y 5
6.
0.5 Y Y Y Y x Y Y 1
0.4 Y Y x Y Y Y Y 1
0.3 x x x Y Y Y Y 3
0.2 x x x Y Y Y Y 3
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2010; Rampersaud et al., 2011; Posafalvi et al., 2013). This is the first study to investigate
the combined effect of multiple factors on the predisposition to DCM. Although our
models do not explain all cases of canine DCM, by combining three factors (PDK4, Chr5
TIGRP2P73097 SNP and an X-linked locus) we show that DCM incidence can be more
accurately predicted (Tables 6–12). Furthermore, as noted above the PDK4 splice site
deletion is not significantly associated with DCM in the European population. But in the
model incorporating only the two known loci, the PDK4 variant improves the odds ratio
for the Chr5 SNP. Collectively these findings indicate that models incorporating multiple
factors are more effective than those incorporating a single factor. This result is important
because it has implications for future studies of the genetics and management of DCM. A
better understanding of the genetic basis of DCM will permit the monitoring and earlier
clinical intervention of high risk individuals thus potentially improving the outcome for
affected individuals.
To assess the accuracy of each model, we performed several statistical tests. For any
model to be considered an accurate representation of observed data it should predict
similar numbers of affected and unaffected individuals at each genotype as have been
reported in the published data. It should also predict a similar DCM frequency to that
found in the population. Secondly, the odds ratios of genotypes and alleles should support
an association of the specific variants with DCM. The models incorporating the two
known DCM loci and an additional X-linked locus with a susceptible allele frequency
of 0.46 for the novel susceptible allele met all such conditions. It is important to note that
this susceptible allele frequency should have been identified by the previous GWAS studies
(Mausberg et al., 2011;Meurs et al., 2012). It is therefore possible that additional cases and
controls are required to complete a comprehensive GWAS analysis of DCM in Dobermans
to establish the function and frequency of this predicted DCM associated locus.
Most predictive models are based on either known or simulated genotypes at multiple
loci (Janssens et al., 2006; Pencina, D’Agostino & Vasan, 2008). Suchmodels do not account
for known effects of genotypes or allow the inclusion of additional as yet unknown,
loci. For example, in this study all individuals possessing the Chr5 CC genotype have
DCM. Our methodology is unique and useful where there are multiple known and
unknown factors which do not fully account for the phenotype. In particular, our approach
accommodates specific gene combinations to lead to disease, rather than incremental risk
factors as is the case in other predictive models (Janssens et al., 2006; Pencina, D’Agostino
& Vasan, 2008). Limitations to our methodology include the number of factors that can
be modelled is limited by the available data. Despite this, our methodology could be
used in other situations. While many phenotypes are the consequence of multiple loci,
there can be some loci which have comparatively more important contribution to the
phenotype (e.g., Strange et al., 2011; Papa et al., 2013). Identifying these loci can be the
first steps in predicting phenotypes (e.g., Hayes et al., 2010; Papa et al., 2013). Following
the identification of loci associated with a trait, our methodology can be used to indicate
what type of additional loci may be influencing the trait of interest, whichmay simplify the
identification of additional loci.
Simpson et al. (2015), PeerJ, DOI 10.7717/peerj.842
CONCLUSIONS
There are many unknown factors involved in the aetiology of canine and human DCM.
In Dobermans, we have identified multigenic effects and a possible X-linked locus as
novel variables influencing DCM risk. While the PDK4 splice site deletion and the Chr5
SNP have both been tested for association with DCM in the European population of
Dobermans, the combined genotype of individuals has not yet been considered (Mausberg
et al., 2011; Owczarek-Lipska et al., 2013). Our model would benefit from further
genotyping of Dobermans at both the PDK4 and Chr5 variants to further validate the
model. Future work is also required to identify X-linked DCM loci if the model is verified
for the known loci. It is also possible that the different combinations of alleles leading to
DCM in the model could affect the time taken to progress from one disease stage to the
next as reported byWess et al. (2010). If validated, our model has implications for current
canine breeding practices and welfare of individuals within the breed. Individuals with
allele combinations more likely to develop DCM can be monitored more intensely than
those with less genetic risk, and mating pairs resulting in deleterious genotypes can be
avoided. This will have improve welfare by reducing the prevalence of DCM-associated
alleles within the population and potentially improving the longevity of affected dogs by
enabling monitoring and earlier clinical management. By utilising similar methodology,
equivalent multigenic effects and possible additional loci could be identified in human
DCM, giving similar benefits to those described for Dobermans.
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